Abvc Biopharma (ABVC) Other Accumulated Expenses (2015 - 2026)

Abvc Biopharma (ABVC) has 8 years of Other Accumulated Expenses data on file, last reported at $523853.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 15.22% year-over-year to $523853.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $523853.0 (down 15.22% YoY) and the FY2025 annual result came in at $470133.0, up 9.31% from the prior year.
• Other Accumulated Expenses improved to $523853.0 in Q1 2026, from $470133.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.2 million in Q1 2022 to a low of -$30143.0 in Q3 2024.
• A 5-year average of $489609.0 and a median of $450120.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses soared 17915.82% — and 2024, when it plunged 106.28%.
• Tracing ABVC's Other Accumulated Expenses over 5 years: stood at $961.0 in 2022, then soared by 17915.82% to $173132.0 in 2023, then jumped by 148.43% to $430107.0 in 2024, then rose by 9.31% to $470133.0 in 2025, then gained by 11.43% to $523853.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $523853.0 (Q1 2026), $470133.0 (Q4 2025), and $575578.0 (Q3 2025), per Business Quant data.